Alumis (ALMS) Price to Sales (2025 - 2026)
Alumis' (ALMS) quarterly Price to Sales came in at 2107.04 in Q2 2026, up 2345.75% year-over-year from 86.15 in Q2 2025, and up 320.29% quarter-over-quarter from 501.33 in Q4 2025.
Powered by 
Analysis
Alumis (ALMS) Price to Sales (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported Price to Sales for 2 consecutive years, with 2107.04 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Price to Sales rose 2345.75% year-over-year to 2107.04 in Q2 2026; TTM through Jun 2026 was 420.75, a N/A change from a year earlier, with the FY2025 full-year figure at 40.21, changed N/A from the prior year.
- Price to Sales was 2107.04 for Q2 2026 at Alumis, up from 501.33 in the prior quarter.
- Over five years, Price to Sales peaked at 2107.04 in Q2 2026 and troughed at 16.66 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,107.04 |
| Dec 31, 2025 | 501.33 |
| Sep 30, 2025 | 187.67 |
| Jun 30, 2025 | 86.15 |
| Mar 31, 2025 | 16.66 |